The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 935
Potential association factors for developing effective peptide-based cancer vaccines
Jiang, C., Li, J., Zhang, W., Zhuang, Z., Liu, G., Hong, W., Li, B., Zhang, X., & Chao, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931612 · Cited by 13
Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients
Grynberg, S., Stoff, R., Asher, N., Shapira‐Frommer, R., Schachter, J., Haisraely, O., Lawrence, Y. R., & Ben‐Betzalel, G. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221131521 · Cited by 13
Blue naevi and the blue tumour spectrum
de la Fouchardière, A. (2022) · Pathology · doi:10.1016/j.pathol.2022.12.342 · Cited by 13
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond
Gerard, C. L., Shum, B., Nathan, P., & Turajlic, S. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100386 · Cited by 14
Self-citationKoch, E. A. T., Petzold, A., Wessely, A., Dippel, E., Eckstein, M., Gesierich, A., Gutzmer, R., Hassel, J. C., Knorr, H. L. J., Kreuzberg, N., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-0993-y · Cited by 12
Self-citationTruex, N. L., Rondon, A., Rössler, S. L., Hanna, C. C., Cho, Y., Wang, B., Backlund, C. M., Lutz, E. A., Irvine, D. J., & Pentelute, B. L. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00625 · Cited by 12
Kolb, M., Forschner, A., Artzner, C. P., Grözinger, G., Said, I., Dittmann, H., & Seith, F. (2023) · Cancers · doi:10.3390/cancers15204942 · Cited by 12
Understanding choroidal nevus risk factors for transformation into melanoma
DeSimone, J. D., Shields, C. N., Kalafatis, N. E., Marous, M. R., Marous, C. L., Shields, J. A., & Shields, C. L. (2023) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2023.10.012 · Cited by 12
Tong, L., Wan, Y., Shi, X., Liu, X., Liu, Z., Li, Y., Zhang, Y., Luo, D., & Zhu, J. (2024) · Cancer Control · doi:10.1177/10732748241253959 · Cited by 12
Engineering T-cell receptor–like antibodies for biologics and cell therapy
Høydahl, L. S., Berntzen, G., & Løset, G. Å. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103224 · Cited by 12
The role of circulating tumor DNA in melanomas of the uveal tract
Zameer, M. Z., Jou, E., & Middleton, M. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509968 · Cited by 13
Kulbay, M., Tuli, N., Mazza, M., Jaffer, A., Juntipwong, S., Marcotte, E., Tanya, S. M., Nguyen, A. X.-L., Burnier, M. N., & Demirci, H. (2025) · Biomedicines · doi:10.3390/biomedicines13010108 · Cited by 12
Yang, M., Jiang, X., Song, M., Feng, W., Chen, Y., Gu, P., & Fan, X. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202415688 · Cited by 12
Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update
Seth, R., Messersmith, H. J., Funchain, P., & Panel, F. T. S. T. F. M. G. E. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00944 · Cited by 12
Vogel, A., Ochsenreither, S., Zager, J. S., Wacker, F. K., & Saborowski, A. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102501 · Cited by 12
Self-citationS100 as Serum Tumor Marker in Advanced Uveal Melanoma
Salzmann, M., Enk, A., & Hassel, J. C. (2023) · Biomolecules · doi:10.3390/biom13030529 · Cited by 12
Self-citationUgurel, S., & Gutzmer, R. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15053_g · Cited by 13
Bauer, S., Larkin, J., Hodi, F. S., Stephen, F., Kapiteijn, E., Schwartz, G. K., Calvo, E., Yerramilli-Rao, P., Piperno-Neumann, S., & Carvajal, R. D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.975642 · Cited by 12
Self-citationPharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review
Sangwan, K., Sharma, V., & Goyal, P. K. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230622151034 · Cited by 12
Wang, Y., Sun, W., & Wang, B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1667282 · Cited by 11
Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy
Battistini, E., Lapuhs, P., Jiménez, A., Garrido-Areal, S., Rivas-Gómez, L., Zagorac, I., Álvarez‐Vallina, L., Alonso, M. J., & Sanjurjo, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02501-9 · Cited by 11
Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma
Espona‐Fiedler, M., Manuel-Manresa, P., Benítez-García, C., Fontova, P., Quesada, R., Soto‐Cerrato, V., & Pérez‐Tomás, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010097 · Cited by 11
Arman, I., Haus‐Cohen, M., & Reiter, Y. (2022) · Cells · doi:10.3390/cells12010027 · Cited by 11
Robinson, H., Eleuteri, A., Sacco, J. J., Hussain, R. N., Heimann, H., Taktak, A. F. G., Damato, B. E., Thompson, A., Allen, T., Kalirai, H., et al. (2023) · Cancers · doi:10.3390/cancers15092610 · Cited by 11
Self-citationGarcía‐Mulero, S., Fornelino, R., Punta, M., Lise, S., Varela, M., del Carpio, L. P., Moreno, R., Costa-García, M., Rieder, D., Trajanoski, Z., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2261278 · Cited by 11
Self-citationMultifactorial Remodeling of the Cancer Immunopeptidome by IFNγ
Newey, A., Yu, L., Barber, L. J., Choudhary, J. S., Bassani‐Sternberg, M., & Gerlinger, M. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0121 · Cited by 11
Innovative drugs promote precision cancer therapy
Huang, X., Zhu, M., Chen, R., Ni, J., Zhao, W., Li, S., Lü, X., Jiao, H., & Cao, X. (2023) · Clinical Cancer Bulletin · doi:10.1007/s44272-023-00002-8 · Cited by 12
Divergent local and systemic antitumor response in primary uveal melanomas
Lucibello, F., Lalanne, A. I., Gac, A. L., Soumare, A., Aflaki, S., Cyrta, J., Dubreuil, L., Mestdagh, M., Salou, M., Houy, A., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232094 · Cited by 11
Self-citationLopes, C. D. H., Xavier, C. B., Torrado, C., Veneziani, A. C., & Megid, T. B. C. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-24-23 · Cited by 11
Li, K., Huang, J., Tan, Y., Sun, J., & Zhou, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05831-2 · Cited by 11
Vitek, L., Goronflot, T., Dutriaux, C., Deleuze, A., Corre, Y. L., Duval-Modeste, A.-B., Fresnard, C., Jeudy, G., Lamoureux, A., Gaudy‐Marqueste, C., et al. (2024) · Acta Dermato Venereologica · doi:10.2340/actadv.v104.41297 · Cited by 11
Zager, J. S., Orloff, M. M., Ferrucci, P. F., Choi, J., Eschelman, D. J., Glazer, E. S., Ejaz, A. M., Howard, J. H., Richtig, E., Ochsenreither, S., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17231-x · Cited by 11
Self-citationJain, M. D., Abramson, J. S., & Ansell, S. M. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473916 · Cited by 11
T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis
Zaïr, Z. M., Butterworth, G., Shalaby, M., Oštarijaš, E., & Thisthlethwaite, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102991 · Cited by 11
Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
Wei, A. Z., Uriel, M., Porcu, A., Manos, M. P., Mercurio, A. C., Caplan, M. M., Hulse, L., Seedor, R. S., Holovatska, M. M., Francis, J. H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961517 · Cited by 11
Self-citationPan, Z., Zhu, H., Zhang, Y., Liao, Q., Sun, Y., Wu, E., Wang, Y., Shi, K., Zhang, Y., Chen, L., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c00005 · Cited by 11
Millar, D. G., Yang, S. Y. C., Sayad, A., Zhao, Q., Nguyen, L. T., Warner, K., Sangster, A. G., Nakatsugawa, M., Murata, K., Wang, B. X., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03413-7 · Cited by 12
Sundaramurthi, H., Tonelotto, V., Wynne, K. J., O’Connell, F., O’Reilly, E., Costa-García, M., Kovácsházi, C., Pendino, M., Kittel, Á., Marcone, S., et al. (2023) · Open Research Europe · doi:10.12688/openreseurope.15973.1 · Cited by 11
Lamas, N. J., Lassalle, S., Martel, A., Nahon‐Estève, S., Macocco, A., Zahaf, K., Lalvée, S., Fayada, J., Lespinet‐Fabre, V., Bordone, O., et al. (2023) · Pathology · doi:10.1016/j.pathol.2023.08.003 · Cited by 11
Zhang, R., Chen, X., Chen, S., Tang, J., Chen, F., Lin, Y. Q., Reinach, P. S., Yan, X., Tu, L., Duan, H., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00682-9 · Cited by 11
Chattopadhyay, C., Bhattacharya, R., Roszik, J., Khan, F. S., Wells, G. A., Villanueva, H. J., Qin, Y. W., Bhattacharya, R., Patel, S. P., & Grimm, E. A. (2022) · Cancers · doi:10.3390/cancers14246247 · Cited by 11
Innovative drugs bring continuous benefits to cancer patients
Huang, X., & Cao, X. (2023) · The Innovation Life · doi:10.59717/j.xinn-life.2023.100043 · Cited by 11
T cell immunotherapy for solid tumors: limitations, progress, and future prospects
Wang, Y., Zhang, B., Wang, Y., Tan, Y., Hu, X., Che, X., & Feng, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755751 · Cited by 11
Tomsitz, D., Kerl, K., French, L. E., & Heinzerling, L. M. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.08.037 · Cited by 10
Hou, W., Zou, Y., Li, J., Jiang, H., Li, J., Wu, J., Zhu, S., Ding, Y., Xu, H., Jia, F., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c05209 · Cited by 10
Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model
Anbari, S., Wang, H., Arulraj, T., Nickaeen, M., Pilvankar, M., Wang, J., Hansel, S. B., & Popel, A. S. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00434-5 · Cited by 10
Minocha, M., Thompson, C. G., Murphy, A., Zhou, Y., Brandl, C., Parkes, A., Chen, X., Yu, B. H., Martínez, P., & Houk, B. E. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01451-7 · Cited by 11
Dalvin, L. A., Andrews-Pfannkoch, C. M., Miley, D. R., Hogenson, T. L., Erickson, S. A., Malpotra, S., Anderson, K. J., Omer, M. E., Almada, L. L., Zhang, C., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.13.60 · Cited by 10
Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer
Abodunrin, F., Olson, D. J., Emehinola, O., & Bestvina, C. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251320280 · Cited by 11
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
Marron, T. U., Luke, J. J., Hoffner, B., Perlmutter, J., Szczepanek, C. M., Anagnostou, V., Silk, A. W., Romero, P. J., Garrett-Mayer, E. S., & Emens, L. A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010760 · Cited by 12
Khan, S. R., & Breadner, D. A. (2025) · Current Oncology · doi:10.3390/curroncol32040206 · Cited by 10
Szabó, I. L., Emri, G., Ladányi, A., & Tı́már, J. (2025) · Cancers · doi:10.3390/cancers17091422 · Cited by 11
Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres
van der Kooij, M. K., Kapiteijn, E., Rutkowski, P. L., Baurain, J., de Koning, L., Speetjens, F. M., Bartoszek, P., Rogala, P., Cornélis, F., Dudzisz‐Śledź, M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115634 · Cited by 10
Self-citationCharacterization of anti-CD3 antibodies in clinically available bispecific T cell engagers
Lee, H., Lee, Y., & Chung, J. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.08.004 · Cited by 10
van den Bosch, Q. C. C., Nguyen, J. Q. N., Brands, T., van den Bosch, T. P. P., Verdijk, R. M., Paridaens, D. A., Naus, N. C., de Klein, A., Kılıç, E., & Brosens, E. (2022) · Cancers · doi:10.3390/cancers14153668 · Cited by 10
Slater, K., Bosch, R., Smith, K. F., Jahangir, C. A., García‐Mulero, S., Rahman, A., O’Connell, F., Piulats, J. M., O’Neill, V., Horgan, N., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1036322 · Cited by 10
Self-citationdel Carpio, L. P., Algarra, M. A., Sabaté-Llobera, A., Rodríguez‐Vida, A., Rossi‐Seoane, S., Ruíz, S., Leiva, D., Ramos, E., Lladó, L., Lorenzo, D., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6058 · Cited by 10
Self-citationCo-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth
Han, A., Mukha, D., Chua, V. Y. L., Purwin, T. J., Tiago, M., Modasia, B., Baqai, U., Aumiller, J. L., Bechtel, N., Hunter, E., et al. (2023) · Cancers · doi:10.3390/cancers15133451 · Cited by 11
Martel, A., Mograbi, B., Roméo, B., Gastaud, L., Lalvée, S., Zahaf, K., Fayada, J., Nahon‐Estève, S., Bonnetaud, C., Salah, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311075 · Cited by 10
Self-citationNew Treatment Horizons in Uveal and Cutaneous Melanoma
Branisteanu, D. E., Porumb‐Andrese, E., Porumb, V., Stărică, A., Moraru, A. D., Nicolescu, A. C., Zemba, M., Brănişteanu, C. I., Brănișteanu, G., & Brănişteanu, D. C. (2023) · Life · doi:10.3390/life13081666 · Cited by 10
Kuang, T., Zhang, L., Qiu, Z., Zhang, Y., & Wang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1261202 · Cited by 10
High resolution HLA genotyping with third generation sequencing technology—A multicentre study
Bühler, S., Nørgaard, M., Steffensen, R., Kløve‐Mogensen, K., Møller, B. K., Großmann, R., Ferrari‐Lacraz, S., & Lehmann, C. (2024) · HLA · doi:10.1111/tan.15632 · Cited by 10
LXS196 for Metastatic Uveal Melanoma - finally some progress
Rodrigues, A., Cosman, R., & Joshua, A. M. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02199-w · Cited by 10
Self-citationYang, M., Li, J., Liu, Z., Zhang, H., Liu, J., Liu, Y., Zhuang, A., Zhou, H., Gu, P., & Fan, X. (2022) · Biomaterials Science · doi:10.1039/d2bm01058e · Cited by 9
Liu, X., Yue, H., Jiang, S., Kong, L., Xu, Y., Chen, Y., Wang, C., Wang, Y., Zhu, X., Kong, Y., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6273 · Cited by 9
The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma
Boudreau, M. W., Tonogai, E. J., Schane, C. P., Xi, M. X., Fischer, J. H., Vijayakumar, J., Ji, Y., Tarasow, T. M., Fan, T. M., Hergenrother, P. J., et al. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000927 · Cited by 9
Subbarayan, R., Srinivasan, D., Balakrishnan, R., Kumar, A., Usmani, S. S., & Srivastava, N. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.05.001 · Cited by 9
Broadening alloselectivity of T cell receptors by structure guided engineering
Karuppiah, V., Sangani, D., Whaley, L. M., Pengelly, R., Uluocak, P., Carreira, R. J., Hock, M., Cristina, P. D., Bartasun, P., Dobrinić, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75140-7 · Cited by 9
Salzler, R. R., DiLillo, D. J., Saotome, K., Bray, K., Mohrs, K., Hwang, H., Cygan, K. J., Shah, D., Rye-Weller, A., Kundu, K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado9371 · Cited by 9
Rosenberg, A. M., & Baker, B. M. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102358 · Cited by 9
Ramtohul, T., Cohen, A., Rodrigues, M. J., Piperno-Neumann, S., Cabel, L., Cassoux, N., Rouïc, L. L.-L., Malaise, D., Gardrat, S., Pierron, G., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01793-8 · Cited by 9
Self-citationTreatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis
Reichstein, D. A., Brock, A. L., Lietman, C., & McKean, M. A. (2022) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000905 · Cited by 9
Herrspiegel, C., Plastino, F., Lardner, E., Seregard, S., Williams, P. A., André, H., & Stålhammar, G. (2023) · BMC Cancer · doi:10.1186/s12885-023-10757-x · Cited by 9
Determinants of overall survival in patients with metastatic uveal melanoma
Demkowicz, P. C., Pointdujour‐Lim, R., Miguez, S. M., Lee, Y., Jones, B. S. C. L., Barker, C. A., Bosenberg, M., Abramson, D. H., Shoushtari, A. N., Kluger, H. M., et al. (2023) · Cancer · doi:10.1002/cncr.34927 · Cited by 9
Self-citationZhang, C., Xiao, J., Fa, L., Jiang, F., Jiang, H., Zhou, L., & Xu, Z. (2023) · BMC Ophthalmology · doi:10.1186/s12886-023-03098-7 · Cited by 9
Némati, F., de Koning, L., Gentien, D., Assayag, F., Henry, E., Raïs, K. A., Pierron, G., Mariani, O., Nijnikoff, M., Champenois, G., et al. (2023) · Current Oncology · doi:10.3390/curroncol30100657 · Cited by 9
Self-citationClinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes
Shannon, A. B., Zager, J. S., & Perez, M. C. (2024) · Cancers · doi:10.3390/cancers16132395 · Cited by 10
The Impact of Spliceosome Inhibition in SF3B1 -Mutated Uveal Melanoma
Nguyen, J. Q. N., Drabarek, W., Leeflang, A. M. C. H. J., Brands, T., van den Bosch, T. P. P., Verdijk, R. M., van de Werken, H. J. G., van Riet, J., Paridaens, D. A., de Klein, A., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.12.11 · Cited by 9
Review of bi-specific therapies in uveal melanoma
Orloff, M. M., Seedor, R. S., & Sato, T. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00442-9 · Cited by 9
Self-citationFüchsl, F., & Krackhardt, A. M. (2022) · Cancers · doi:10.3390/cancers14174192 · Cited by 9
Long, M., Mims, A. S., & Li, Z. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2131569 · Cited by 9
Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma
Baqai, U., Kurimchak, A., Trachtenberg, I. V., Purwin, T. J., Haj, J. I., Han, A., Luo, K., Pachon, N. F., Jeon, A., Chua, V. Y. L., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105418 · Cited by 8
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Masmoudi, D., Vialaret, J., Hirtz, C., & Alix‐Panabières, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13665 · Cited by 8
Germline Variants in Patients Affected by Both Uveal and Cutaneous Melanoma
Johansson, P. A., Palmer, J. M., McGrath, L. A., Warrier, S., Hamilton, H. R., Beckman, T. J., D'Mellow, M. G., Brooks, K. M., Glasson, W. J. H., Hayward, N. K., et al. (2024) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13199 · Cited by 8
Kapetanovic, E., Weber, C. R., Bruand, M., Pöschl, D., Kucharczyk, J., Hirth, E., Dietsche, C. L., Khan, R. A., Wagner, B., Belli, O., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01255-x · Cited by 8
Viral sequence determines HLA-E-restricted T cell recognition of hepatitis B surface antigen
Murugesan, G., Paterson, R. L., Kulkarni, R., Ilkow, V. F., Suckling, R. J., Connolly, M. M., Karuppiah, V., Pengelly, R., Jadhav, A., Donoso, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54378-9 · Cited by 8
Lin, H., Case, R. B., Wei, K. Y., Eres, I. E., Alba, B. M., Kaner, J., Wu, Y.-C., Yamawaki, T., Mostafavi, M., Zhou, H., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102117 · Cited by 8
Althafar, Z. M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1614325 · Cited by 8
Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations
del Carpio, L. P., Varela, M., Portu, M., Villatoro, S., Purqueras, E., Gomà, M., Lorenzo, D., Lladó, L., Gutiérrez, C., Ramos, E., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115591 · Cited by 8
Self-citationUveal Melanoma UK national guidelines: 2023 update
Carter, T. J., Broadfoot, J., Coupland, S. E., Damato, B. E., Evans, H., Fenwick, S. W., Khoja, L., Krausa, T., Lewis, R., Nathan, P., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115687 · Cited by 8
Self-citationWermke, M., Ochsenreither, S., Jaeger, D., Becker, H., Bleckmann, A., Bozorgmehr, F., Chatterjee, M., Groepper, S., Haenel, M., Hecker, J. S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04455-x · Cited by 8
Self-citationTrivedi, D. B., Aldulaimi, N., Karydis, I., Wheater, M. J., Modi, S., Stedman, B., Karavias, D. D., Primrose, J. M., Pearce, N., & Takhar, A. S. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000867 · Cited by 8
Rossi, E., Cellini, F., Pagliara, M. M., Sammarco, M. G., Pedone, R. R., Lancellotta, V., Tagliaferri, L., Quirino, M., Gambacorta, M. A., Blasi, M. A., et al. (2023) · Cancers · doi:10.3390/cancers15020493 · Cited by 8
Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals
Croley, C. R., Pumarol, J., Delgadillo, B. E., Cook, A. C., Day, F., Kaceli, T., Ward, C. C., Husain, I., Husain, A., Banerjee, S., et al. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108479 · Cited by 8
Uveal melanoma modeling in mice and zebrafish
van den Bosch, Q. C. C., de Klein, A., Verdijk, R. M., Kılıç, E., & Brosens, E. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189055 · Cited by 8
Personalized treatment approaches in intraocular cancer
Liu, Y., Rokohl, A. C., Guo, Y., Yao, K., Fan, W., & Heindl, L. M. (2024) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2024.03.005 · Cited by 8
Ghali, H., Dugan, M. M., Aflatooni, S., Boby, A., DePalo, D. K., Laborde, J., Choi, J., Ahmed, A. F., & Zager, J. S. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16039-5 · Cited by 8
Adoptive T Cell Therapy Targeting MAGE-A4
Chandora, K., Chandora, A., Saeed, A., & Cavalcante, L. L. (2025) · Cancers · doi:10.3390/cancers17030413 · Cited by 8
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma
Leonard‐Murali, S., & Kammula, U. S. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2478808 · Cited by 8
T cell engagers in solid tumors kick the door down
Miguel, M. J. D., & Calvo, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.005 · Cited by 8
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
